Lemsip Cough for Chesty Cough 50mg/5ml oral solution

Country: United Kingdom

Language: English

Source: MHRA (Medicines & Healthcare Products Regulatory Agency)

Active ingredient:

Guaifenesin

Available from:

Reckitt Benckiser Healthcare (UK) Ltd

ATC code:

R05CA03

INN (International Name):

Guaifenesin

Dosage:

10mg/1ml

Pharmaceutical form:

Oral solution

Administration route:

Oral

Class:

No Controlled Drug Status

Prescription type:

Valid as a prescribable product

Product summary:

BNF: 03090200; GTIN: 5000158064034 5011417566817

Summary of Product characteristics

OBJECT 1
LEMSIP COUGH CHESTY
Summary of Product Characteristics Updated 14-Dec-2017 | Reckitt
Benckiser Healthcare (UK) Ltd
1. Name of the medicinal product
Lemsip Cough for Chesty Cough 50mg/5ml Oral Solution
2. Qualitative and quantitative composition
Guaifenesin 50mg/5ml
Excipient(s):
Sucrose: 3.965 g per 5ml dose
Sodium: 3.66 mg (0.16mmol) per 5ml dose
For full list of excipients, see section 6.1 .
3. Pharmaceutical form
Oral solution
4. Clinical particulars
4.1 Therapeutic indications
Symptomatic relief of deep chesty coughs and to soothe the throat.
4.2 Posology and method of administration
For oral administration.
Under 12 years: On medical advice only
To be taken three or four times daily.
Glass bottle
Adults and children 12 years and over: two to four 5ml spoonfuls.
PETE plastic bottle
Adults and children 12 years and over: 10 ml dose (fill measure cup to
10 ml); 15 ml (one 10 ml measure
in cup followed by a 5 ml measure); 20 ml (10 ml taken twice). Rinse
the measure cup after use.
4.3 Contraindications
Hypersensitivity to guaifenesin or to any of the excipients.
4.4 Special warnings and precautions for use
This medicine contains 0.16 mmol (or 3.66 mg) sodium per 5 ml dose. To
be taken into consideration by
patients on a controlled sodium diet.
Contains 3.965 g of sucrose per 5 ml dose. This should be taken into
account in patients with diabetes
mellitus.
Patients with rare hereditary problems of fructose intolerance,
glucose-galactose malabsorption or
sucrase-isomaltase insufficiency should not take this medicine.
4.5 Interaction with other medicinal products and other forms of
interaction
If urine is collected within 24 hours of a dose of the medicinal
product, a metabolite of guaifenesin may
cause a colour interference with laboratory determinations of urinary
5-hydroxyindoleacetic acid (5-
HIAA) and vanillylmandelic acid (VMA).
Guaifenesin may increase the rate of absorption of paracetamol.
4.6 Pregnancy and lactation
Guaifenesin has been linked with an increased risk of neural tube
defects in a smal